FPF
OCRX

FNY Partners Fund’s Ocera Therapeutics, Inc. OCRX Stock Holding History

FNY Partners Fund’s Portfolio OCRX Stock Details OCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6,400
Closed -$8K – 1419
2017
Q1 		$8K Buy
+6,400
New +$8.15K ﹤0.01% 1140

Other funds holding OCRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FNY Partners Fund's OCRX Position: Q2 2017 in Review

FNY Partners Fund sold out of Ocera Therapeutics, Inc. (OCRX) in Q2 2017, closing a stake of 6,400 shares — an estimated $8K sold.

FNY Partners Fund first reported a position in OCRX in Q1 2017 and held it in 1 quarter. The position peaked at $8K in Q1 2017. 24 funds tracked by Wall St. Rank hold OCRX as of Q2 2017.

  • FNY Partners Fund reported no remaining Ocera Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • FNY Partners Fund sold 6,400 Ocera Therapeutics, Inc. shares in Q2 2017, an estimated $8K.
  • FNY Partners Fund first reported a position in Ocera Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • FNY Partners Fund's Ocera Therapeutics, Inc. position peaked at $8K in Q1 2017.
  • 24 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q2 2017.

Based on FNY Partners Fund's 13F filing for Q2 2017, filed 10 Aug 2017.